The former CEO of Chinese sequencing giant BGI has started his new venture, iCarbonX. As expected, iCarbonX will build a deep, broad pool of health data and develop an artificial intelligence platform to dig into the resource for insights into how to treat diseases.
The FDA is trying to learn more about virtual clinical trials, the bring-your-own-device (BYOD) model of provisioning and other aspects of today's tech-enabled research environment. The regulator has set up a docket to gather feedback on how researchers are using technology and what barriers are stopping more widespread adoption.
Verge Genomics has raised $4 million to finance a computer-based drug discovery program targeting neurological disorders. The plan is to map all the genes implicated in a disease, using technology that Verge compares to Google's search engine, and find drugs that can hit each of the targets simultaneously.
The existence of an ever-present pool of people who struggle to afford medicines and online bazaars that can meet their needs has brought two new groups to the hidden underbelly of the internet: Big Pharma and cash-strapped seniors.
Dovetail Genomics has started offering a de novo whole genome assembly service.
The search at Apple, Google and other members of the tech elite for new business opportunities is pushing them to recruit from outside of their core fields. And whether the sector being targeted is artificial intelligence, self-driving cars or life sciences, the result is the same: a tug-of-war with incumbents for talent.
This year is shaping up to be a pivotal one for Nimbus Therapeutics. Having pocketed $43 million from a clutch of big-name backers in March, the computational chemistry specialist has persuaded Roche's Genentech to license an interleukin-1 receptor-associated kinase 4 inhibitor program.
The joint venture set up by Novartis and Qualcomm has teamed up with Lux Capital to funnel $6.5 million into Science 37. Los Angeles, CA-based Science 37 will use the cash to step up the expansion of its virtual, tech-enabled model of clinical trial services.
Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.
The Scripps Research Institute has teamed up with two German research centers to improve the quality of induced pluripotent stem cells. Researchers at Scripps and its collaborators will apply next-generation sequencing to the task of analyzing iPSCs that could improve the accuracy of preclinical disease and toxicity models.
The software, called PKPlus, is seen by Simulations Plus as a way to step up competition in the market for noncompartmental analysis software.
Genomics England is to work with LabKey Software to develop a data-management platform that meets the needs of the 100,000 Genomes Project. The deal puts the open-source LabKey Server platform at the center of the infrastructure the massive sequencing project will use to integrate and share data.
J. Craig Venter has unveiled the scope of the Health Nucleus testing service being offered by Human Longevity Inc. For $50,000, HLI will perform a battery of sequencing, imaging and laboratory tests to build a picture of the health of an individual--while adding a wealth of information to its burgeoning database.
23andMe has bounced back from a difficult couple of years with a $115 million fundraising round that values the company at $1.1 billion. The cash will enable 23andMe to set up new lab space to fire up its nascent in-house drug discovery program and invest in a next-generation sequencing facility.
WuXi NextCODE has added another country to its growing list of large-scale sequencing projects. Sidra Medical and Research Center, which is involved with the Qatar Genome Project, has turned to WuXi NextCODE for help.
UBiome has become the first for-profit organization to roll out an app for Apple ResearchKit, the tech giant's open-source study platform. The program is combining a ResearchKit-enabled app with uBiome's microbiome test to generate data that may one day support biopharma R&D.
When Gilead's Sovaldi and AbbVie's Viekira Pak came to market, physicians had little real-world evidence for either drug on which to base their prescribing decisions. In an attempt to fill this gap and find out what happens to hepatitis C patients between physician visits, Boston Children's Hospital has created an app for Apple ResearchKit.
GlaxoSmithKline has provided a glimpse at just how much information about the real-world use of drugs is online. In a trawl of Facebook and Twitter, the Big Pharma found 21 million mentions of its products--and the data have already led to the recall of a GSK product.
The University of California, San Francisco (UCSF) has snagged $9.75 million to build a platform for the remote collection of research data. UCSF will use the cash to build out its mobile data gathering toolkit, giving it the capabilities to support large-scale, geographically-dispersed research programs.